Raghav Govindarajan, MD
Neuromuscular Medicine · O Fallon, ILNPI 1639481914
Payments from drug & device makers
Across 1,244 payments — averaging $2260.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$1.4M
- AstraZeneca$313K
- Argenx US, Inc.$222K
- UCB SA$207K
- Catalyst Pharmaceuticals, Inc.$117K
- Regeneron$79K
- plus $517K from 28 others
Across 6 payments — averaging $5208.96 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$31K
What the payments were for
- Consulting fees$192,78722%
- Speaking & faculty fees$572,50866%
- Travel & lodging$89,71710%
- Food & beverage$16,0132%
- Education$1410%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VYVGART$157,681
- SOLIRIS$120,314
- NURTEC ODT$109,496
- ULTOMIRIS$72,174
- QULIPTA$50,020
- UBRELVY$43,084
- HYQVIA$37,281
- VYVGART HYTRULO$35,014
- Rystiggo$28,902
- Symbravo$25,685
- Zilbrysq$20,964
- Radicava$19,016
- UPLIZNA$18,499
- Enspryng$7,614
- Non-Covered Product$2,160
- Duopa$1,650
- TEGSEDI$1,540
- FIRDAPSE$1,200
- EXSERVAN$550
- Hizentra$122
How this compares
$2,812,406 in reported general payments places this provider in the 95th percentile of 21 neuromuscular medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyvgartEfgartigimod Alfa-Fcab | 15 | $1,006,692 |
| Vyvgart HytruloEfgartigimod-Hyaluronidas-Qvfc | 12 | $732,129 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 24 | $354,472 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 31 | $288,991 |
| UbrelvyUbrogepant | 113 | $173,121 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 11 | $152,467 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 18 | $122,808 |
| QuliptaAtogepant | 97 | $118,792 |
| Nurtec OdtRimegepant Sulfate | 55 | $106,632 |
| FingolimodFingolimod Hcl | 12 | $86,619 |
| Aimovig AutoinjectorErenumab-Aooe | 44 | $35,941 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 458 | $10,798 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 12 | $8,561 |
| Lacosamide | 78 | $8,052 |
| TrileptalOxcarbazepine | 12 | $7,264 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Argenx US, Inc.Vyvgart, Vyvgart Hytrulo | $222,330 | $1,738,82127 claims |
| PfizerOctagam, Nurtec Odt | $15,956 | $461,10579 claims |
| AbbVieUbrelvy, Qulipta | $66,162 | $291,913210 claims |
| CSL BehringPrivigen | $26,122 | $288,99131 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $48,212 | $122,80818 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 21 neuromuscular medicine providers in Illinois.
Other neuromuscular medicine in O Fallon
- Senda Ajroud DrissChicago$1.4M
- Arjun SethChicago$755K
- Erik PioroChicago$515K
- Abigail SchwaedeChicago$175K
- Robert KalbChicago$22K
- Matthew BaerElgin$15K
- Daniela MenichellaChicago$11K
- Mohammad AlsharabatiPalos Heights$7K
- Robert SufitChicago$4K
- Richard HarveyChicago$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.